The Centers for Disease Control and Prevention has updated the guidance for evaluation of persons under investigation for coronavirus disease 2019 (COVID-19), expanding the criteria to a wider group of symptomatic patients.
Study findings suggest the benefits of continuing ACEi or ARB therapy outweigh the risks in CKD patients with an eGFR less than 30 mL/min/1.73 m2.
Mean survival benefits varied from 6 months to 3 years for intensive versus standard BP control.
No cardiovascular benefits found with chlorthalidone versus hydrochlorothiazide for hypertension treatment.
Compared with chlorthalidone and lisinopril, amlodipine associated with lower risk for gout.
Medication doses do not need to be reduced in response to symptomless orthostatic hypotension, authors say.
Risk for hypertensive disorder highest in women with estimated date of conception in June, August.
No real benefit seen for adults ≥80 years with lower cognitive function.
Steeper increase in BP seen as early as the third decade in women, continued through life course.
Hyperuricemia may represent a risk factor for stroke, and severe hypertension may mediate this association.
